Table 1 Clinical characteristics of patients with COVID-19 at admission
All patients (n = 53) | ^Wuhan (n = 30) | ^Non-Wuhan (n = 23) | p value | |
|---|---|---|---|---|
Age: Mean (SD), years | 50.2 (15.2) | 52.2 (15.1) | 47.6 (15.3) | 0.279‡ |
Sex, Female: No., (%) | 31/53 (58.5%) | 16/30 (53.3%) | 15/23 (65.2%) | 0.384|| |
Signs and symptoms: No., (%) | ||||
Fever | 47/53 (88.7%) | 27/30 (90%) | 20/23 (87%) | 1.000|| |
< 37.5 | 4/53 (7.5%) | 2/30 (6.7%) | 2/23 (8.7%) | 1.000|| |
37.5–38.5 | 30/53 (56.6%) | 17/30 (56.6%) | 13/23 (56.5%) | 0.992|| |
> 38.5 | ||||
Cough and sputum production | ||||
Myalgia or arthralgia | 10/53 (18.9%) | 5/30 (16.7%) | 5/23 (21.7%) | 0.640|| |
Chill | 7/53 (13.2%) | 6/30 (20.0%) | 1/23 (4.3%) | 0.208|| |
Shortness of breath | 9/53 (17.0%) | 5/30 (16.7%) | 4/23 (17.4%) | 1.000|| |
Fatigue | 18/53 (34.0%) | 10/30 (33.3%) | 8/23 (34.8%) | 0.912|| |
Nasal congestion | 6/53 (11.3%) | 3/30 (10.0%) | 3/23 (13.0%) | 1.000|| |
Headache | 8/53 (15.1%) | 6/30 (20.0%) | 2/23 (8.7%) | 0.452|| |
Throat discomfort | 9/53 (17.0%) | 7/30 (23.3%) | 2/23 (8.7%) | 0.299|| |
Nausea or vomiting | 7/53 (13.2%) | 4/30 (13.3%) | 3/23 (13.0%) | 1.000|| |
Diarrhea | 1/53 (1.9%) | 1/30 (3.3%) | 0/23 | 1.000|| |
Coexisting disorders: No., (%) | ||||
Diabetes | 4/53 (7.5%) | 2/30 (6.7%) | 2/23 (8.7%) | 1.000|| |
Hypertension | 9/53 (17.0%) | 4/30 (13.3%) | 5/23 (21.8%) | 0.661|| |
Cardiovascular disease | 3/53 (5.7%) | 2/30 (6.7%) | 1/23 (4.3%) | 1.000|| |
Hyperlipidemia | 1/53 (1.9%) | 0/30 | 1/23 (4.3%) | 0.434|| |
Hepatitis B infection | 3/53 (5.7%) | 3/30 (10.0%) | 0/23 | 0.249|| |
Cancer | 3/53 (5.7%) | 2/30 (6.7%) | 1/23 (4.3%) | 1.000|| |
Time from onset to admission, Median (IQR) | 5.0 (4.0–7.0) | 4.5 (3.8–6.3) | 5.0 (4.0–7.0) | 0.364‡‡ |
^Disease severity: No., (%) | ||||
Non-severe | 44/53 (83.0%) | 23/30 (76.7%) | 21/23 (91.3%) | 0.299|| |
Severe | 9/53 (17.0%) | 7/30 (23.3%) | 2/23 (8.7%) | |